Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06865482 · ClinicalTrials.gov registry record
Clinical Course Of Disease In Participants With FA-CM
A clinical trial of Cardiomyopathy and Friedreich Ataxia, sponsored by Lexeo Therapeutics.
- Recruiting
- Registry status
- 65
- Enrollment target
- 10
- Study locations
NCT06865482: Recruiting study of Cardiomyopathy and Friedreich Ataxia, sponsored by Lexeo Therapeutics.
NCT06865482 is a study of Cardiomyopathy and Friedreich Ataxia that is actively recruiting participants, run by Lexeo Therapeutics. The registered enrollment target is 65 participants, below the 554-participant average among 25 other Cardiomyopathy trials with a reported enrollment target (88% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06865482, a study of Cardiomyopathy and Friedreich Ataxia, is actively recruiting participants, sponsored by Lexeo Therapeutics.
- RECRUITING
- Registry status
- 65 participants
- Enrollment target
- 10
- Study locations
Study Summary
Characteristics and clinical course of disease In participants with cardiomyopathy associated with Friedreich Ataxia (CLARITY-FA)
Primary Outcome
Change from baseline in left ventricular mass index (LVMi)
Conditions Studied
Study Locations (10)
Other
- Motol University Hospital and the Second Faculty of Medicine - Prague
- Institut de Cardiologie Hopital Pitie Salpetriere - Paris
California
- University of California San Diego - La Jolla
Florida
- University of South Florida - Tampa
Indiana
- Indiana University - Riley Children's Health - Indianapolis
Massachusetts
- Boston Children's Hospital - Boston
Missouri
- Washington University School of Medicine in St. Louis - St Louis
Ohio
- Cincinnati Children's Hospital - Cincinnati
Quebec
- Centre Hospitalier de Universite de Montreal (CHUM) - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2027-09 |
What NCT06865482 shows while recruiting
NCT06865482 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 554-participant average among 25 other Cardiomyopathy trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Cardiomyopathy appearing as the primary indexed condition, and to 0 interventions.
NCT06865482 lists 10 locations in 9 states (Other, California, Florida).
Frequently Asked Questions
What is clinical trial NCT06865482 about?
NCT06865482 is a clinical study titled "Clinical Course Of Disease In Participants With FA-CM". Characteristics and clinical course of disease In participants with cardiomyopathy associated with Friedreich Ataxia (CLARITY-FA)
What is the current status of trial NCT06865482?
This trial is currently recruiting. The enrollment target is 65 participants. The study started on 2025-09-30. Estimated completion is 2027-09.
What conditions does trial NCT06865482 study?
This clinical trial studies the following conditions: Cardiomyopathy, Friedreich Ataxia.
Who is sponsoring clinical trial NCT06865482?
This trial is sponsored by Lexeo Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06865482 being conducted?
This trial has 10 study locations across California, Florida, Indiana, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06865482's enrollment target sits among peer trials
65 15th of 25 higher than 11 of 25 other Cardiomyopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiomyopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
RECRUITING
-
Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
RECRUITING · Phase 4
-
Molecular Imaging of Primary Amyloid Cardiomyopathy
RECRUITING · NA
-
Impella Reverse Remodeling in End-Stage Heart Failure
RECRUITING
-
Genetics of Cardiovascular and Neuromuscular Disease
RECRUITING
-
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI